Urolithin A

The safety evidence for urolithin A supplementation is currently very limited, with most available data coming from animal studies rather than comprehensive human clinical trials.

Known Side Effects

Evidence is extremely thin regarding documented side effects in humans. The clinical trials listed (NCT04783207, NCT05921266, NCT05735886) have been completed but their safety results are not provided in the available evidence. Without access to these trial outcomes, specific side effect profiles cannot be established.

Contraindications and Populations That Should Avoid It

No established contraindications are documented in the provided evidence. However, this absence likely reflects limited safety data rather than confirmed safety across all populations.

Drug Interactions

No drug interaction data is available in the provided evidence. Given that some preclinical studies suggest urolithin A affects cellular pathways like AMPK-mTOR signaling and β-catenin pathways, potential interactions with medications targeting these systems cannot be ruled out, but no specific interactions have been documented.

Special Populations

The provided evidence includes one study in postmenopausal women examining polyphenol effects (which may include urolithin A precursors), but no specific safety data for pregnant women, nursing mothers, children, or individuals with chronic medical conditions is available.

Critical Evidence Gap

The safety profile of urolithin A remains poorly characterized in humans. While several clinical trials have been completed, their safety outcomes are not included in the available evidence. Most research has focused on efficacy endpoints in animal models rather than comprehensive human safety assessment.

---

This information is for educational purposes only and does not constitute medical advice. Consult with a healthcare provider before using urolithin A supplements, especially given the limited human safety data currently available.